RxDoctor Payments Data

Adam Hetz, PA

Physician Assistant · Blaine, MNNPI 1205107422

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $122,345 of the $156,174 with a category attached, or 78.3%. 24 manufacturers reported payments, led by UCB, Inc. at 32.9% of the total. 2025 is the largest year on record at $54,789, more than ten times the $3,275 reported in 2021. Among physician assistant clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$156,174in general payments, 2019–2025

Across 431 payments — averaging $362.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$51K
  • Johnson & Johnson$35K
  • Sanofi$28K
  • Janssen Scientific Affairs, LLC$19K
  • Regeneron Healthcare Solutions, Inc.$12K
  • Arcutis Biotherapeutics, Inc.$4K
  • plus $7K from 18 others

What the payments were for

  • Consulting fees$13,5489%
  • Speaking & faculty fees$122,34578%
  • Travel & lodging$13,5709%
  • Food & beverage$6,7044%
  • Education$70%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$156,174 in reported general payments places this provider in the 95th percentile of 3,121 physician assistant providers in Minnesota.

See all physician assistant providers in Minnesota

Medicare billing

Part B allowed, 2024
$51,790
Medicare patients
201
Services billed
2,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab33$150,941
Cosentyx Unoready PenSecukinumab14$148,212
OtezlaApremilast27$131,952
Doxycycline Monohydrate62$2,349
Azelaic Acid14$2,237
Betamethasone Dipropionate58$2,014
Fluorouracil18$1,457
Ketoconazole79$1,411
Clobetasol Propionate50$1,366
Tacrolimus15$1,296
Triamcinolone Acetonide122$1,291
Metronidazole14$914
Clindamycin Phosphate37$867
Gabapentin17$483
MethotrexateMethotrexate Sodium14$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$41$131,95227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,121 physician assistant providers in Minnesota.

Other physician assistant in Blaine

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →